Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANKRD13C divergent transcript (ANKRD13C-DT), also known as HHLA3 and other aliases, is classified as a long non-coding RNA (lncRNA) gene in humans[4][7]. While the gene is annotated and known to exist, there is currently no confirmed protein product, and its function remains uncharacterized[4][10]. The alternative names reflect historical annotations linking it to putative protein products and associations with endogenous retrovirus-related sequences, but there is no established evidence of physiological or pathological roles[4][10]. ANKRD13C-DT is not considered a therapeutic target, receptor, enzyme, transporter, or transcription factor, and there are no known drugs, biomarkers, or documented disease associations directly linked to it[4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ANKRD13C divergent transcript (ANKRD13C-DT).